ArticleFrontiers in oncology2021

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study.

Li Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.